Total item
Cart Subtotal
$0.00 VEGFR
| Catalog No. | Inhibitor Name | VEGFR1 | VEGFR2 | VEGFR3 | Other |
|---|---|---|---|---|---|
| A10001 | Sorafenib Tosylate | ** | Raf-1,B-Raf,B-Raf (V599E) | ||
| A10880 | Sunitinib Malate | * | Kit,FLT3,PDGFRβ | ||
| A10996 | Cabozantinib | *** | **** | *** | c-Met,Kit,Axl |
| A10080 | Ponatinib | **** | Abl,PDGFRα,FGFR1 | ||
| A10103 | Axitinib | **** | **** | **** | PDGFRβ,Kit,PDGFRα |
| A10998 | Foretinib | *** | **** | **** | Met,Tie-2,RON |
| A10963 | Vandetanib | ** | * | ||
| A10137 | Nintedanib | ** | *** | *** | LCK,FLT3,FGFR2 |
| A10250 | Regorafenib | *** | **** | * | RET,Raf-1,Kit |
| A11518 | Pazopanib HCl | *** | ** | * | FGFR,PDGFR,c-Kit |
| A10185 | Cediranib | *** | **** | **** | c-Kit,PDGFRβ,FGFR1 |
| A10703 | PD173074 | * | FGFR1,c-Src | ||
| A11411 | Dovitinib | *** | *** | *** | FLT3,c-Kit,FGFR1 |
| A10025 | Linifanib | **** | **** | * | CSF-1R,FLT3,Kit |
| A10967 | Vatalanib 2HCl | * | ** | * | PDGFRβ,c-Kit,c-Fms |
| A10773 | RAF265 | ** | B-Raf | ||
| A10101 | Tivozanib | ** | *** | ** | EphB2,PDGFRα,PDGFRβ |
| A10608 | Motesanib Diphosphate | **** | **** | *** | Kit,RET,PDGFR |
| A10340 | Lenvatinib | ** | **** | *** | PDGFRβ,FGFR1,PDGFRα |
| A10953 | Orantinib | * | PDGFRβ,FGFR1 | ||
| A10254 | Brivanib | * | ** | FGFR1 | |
| A10587 | MGCD-265 | **** | **** | **** | Met,RON,Tie-2 |
| A10043 | AEE788 | * | * | * | EGFR,HER2/ErbB2,c-Abl |
| A10352 | ENMD-2076 | * | ** | FLT3,RET,Aurora A | |
| A10679 | OSI-930 | *** | *** | CSF-1R,LCK,C-Raf | |
| A10248 | CYC116 | ** | Aurora A,Aurora B,FLT3 | ||
| A10502 | Ki8751 | **** | c-Kit,PDGFRα,FGFR2 | ||
| A10903 | Telatinib | *** | **** | c-Kit,PDGFRα | |
| A11518 | Pazopanib | *** | ** | * | FGFR,PDGFR,c-Kit |
| A10504 | KRN 633 | * | * | * | PDGFRα,c-Kit,BTK |
| A13377 | SAR131675 | ** | |||
| A10198 | Dovitinib Dilactic Acid | *** | *** | *** | FLT3,c-Kit,FGFR1 |
| A11407 | Apatinib | **** | RET,c-Kit,c-Src | ||
| A10154 | BMS-794833 | ** | Met | ||
| A10162 | Brivanib Alaninate | * | ** | FGFR1 | |
| A11396 | Golvatinib | ** | c-Met | ||
| A11954 | ZM 323881 HCl | **** | |||
| A11955 | ZM 306416 | * | Src,Abl | ||
| A16342 | BFH772 | **** | |||
| A11558 | SU5402 | ** | FGFR1,PDGFRβ | ||
| A12437 | Semaxanib | * | |||
| A11244 | LY2874455 | *** | FGFR2,FGFR1,FGFR4 | ||
| A13234 | SKLB1002 | ** | |||
| A14156 | AZD2932 | *** | PDGFRβ,Flt3,c-Kit | ||
| A10893 | Taxifolin (Dihydroquercetin) | ||||
| A11772 | CP-547632 | *** | FGFR | ||
| A12693 | BAW2881 (NVP-BAW2881) | * | *** | * | C-Raf-1,B-RAFV599E,c-Abl |
| A13465 | SKLB610 | * | PDGFR, FGFR2 | ||
| A13819 | TG 100801 | **** | *** | FGFR1, Fyn, Src | |
| A13820 | TG 100572 | **** | *** | FGFR1, Fyn, Src | |
| A14387 | ltiratinib (DCC2701) | *** | MET, TIE2, TRK | ||
| A15073 | E-3810 | *** | ** | *** | FGFR-1, FGFR-2 |
| A15287 | ZM323881 | **** | |||
| A15792 | BMS-817378 | *** | c-Met |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
-
E-3810
Catalog No. A15073 VEGFR/FGFR InhibitorE-3810 is a potent and selective dual inhibitor of VEGF and FGF receptors with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM and 82.5 nM for VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1 and FGFR-2, respectively. Learn More -
SU10944
Catalog No. A15760 VEGFR InhibitorSU10944 is a small molecule kinase inhibitor of VEGFR that inhibits neovascularization and permeability, and is distributed to the eye upon systemic delivery. Learn More -
ZM323881
Catalog No. A15287 VEGFR InhibitorZM323881 is a potent and selective inhibitor of human vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) with IC50 value of 2 nM. Learn More -
Vandetanib HCl
Catalog No. A15271 VEGFR inhibitorVandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM. Learn More -
TG 100801 HCl
Catalog No. A15261 VEGFr2 inhibitorTG 100801 is the prodrug of TG 100572 (HY-10184), TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively. Learn More -
TG 100572 HCl
Catalog No. A15260 VEGFR2/Src kinase inhibitorTG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM for VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively. Learn More -
SU14813 double bond Z
Catalog No. A15250 VEGFR InhibitorSU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3). Learn More -
N-Desethyl Sunitinib
Catalog No. A15182 VEGFR/PDGFRβ/KIT inhibitorN-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively). Learn More -
R1530
Catalog No. A13111 Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitorR1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. Learn More -
SKLB1002
Catalog No. A13234 VEGFR inhibitorSKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation. Learn More -
TG 100572
Catalog No. A13820 -
TG 100801
Catalog No. A13819 VEGFR2/Src inhibitorTG 100801 is a VEGFR2 targeting prodrug currently in a clinical trial. The active form is TG100572. Learn More -
Ki 20227
Catalog No. A11472 M-CSFR, CSF1R inhibitorKi 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R). Learn More -
SAR131675
Catalog No. A13377 VEGFR3 InhibitorSAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Learn More -
SKLB610
Catalog No. A13465 VEGFR inhibitorSKLB610 is a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Learn More -
AZD 2932
Catalog No. A14156 mutil-targeted protein tyrosine kinase inhibitorAZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively. Learn More -
Toceranib (PHA 291639, SU 11654)
Catalog No. A11581 c-Kit, PDGFR, VEGFR inhibitorToceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. Learn More -
SU-5402
Catalog No. A11558 VEGFR/FGFR/EGFR inhibitorSU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively). Learn More -
ZM 306416 hydrochloride
Catalog No. A11955 VEGFR InhibitorZM 306416 is a VEGF receptor tyrosine kinase inhibitor that inhibits KDR (IC50 = 100 nM) and Flt (IC50 = 2 uM) tyrosine kinases. Learn More -
(-)-Catechin gallate
Catalog No. A12027 (-)-Catechin gallate is an antioxidant constituent of green tea. At uM concentrations, inhibits VEGF-induced tyrosine phosphorylation. Learn More -
LY 2874455
Catalog No. A11244 FGFR/VEGFR2 inhibitorLY2874455 is a novel and potent FGFR/VEGFR Inhibitor. Learn More -
E-7050 (Golvatinib)
Catalog No. A11396 E7050 (also known as golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. Learn More -
SU 5416 (Semaxinib)
Catalog No. A12437 VEGFR InhibitorSU 5416 is an inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET. Learn More -
CP-547632
Catalog No. A11772 VEGFR2 inhibitorCP-547632 is a novel, potent vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor Learn More -
Motesanib (AMG706)
Catalog No. A11496 VEGFR InhibitorMotesanib (AMG706) is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors with IC?? values of 2 nM (VEGFR1), 3 nM (VEGFR2), 6 nM (VEGFR3), 84 nM (PDGFR), and 8 nM (Kit). Learn More -
SU14813
Catalog No. A11557 VEGFR InhibitorSU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3) Learn More -
Fruquintinib
Catalog No. A14393 VEGFR inhibitorFruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Learn More -
JI-101
Catalog No. A13545 VEGFR2/PDGFRβ/EphB4 inhibitorJI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Learn More -
R916562
Catalog No. A19374 Axl/VEGFR2 inhibitorR916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis. Learn More -
Acrizanib
Catalog No. A19384 VEGFR-2 inhibitorAcrizanib is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-KDR. Learn More -
Vorolanib
Catalog No. A19394 VEGFR/PDGFR inhibitorVorolanib (CM082; X-82) is an orally active, multikinase VEGFR/PDGFR inhibitor. Learn More -
-
New
SU 5205
Catalog No. A17153 -
-
-
New
SU-5408
Catalog No. A17154 VEGFR2 Kinase InhibitorSU-5408, also known as VEGFR2 Kinase Inhibitor I, is a potent, cell-permeable inhibitor of mouse VEGFR2 kinase with IC50 value of 70 nM. Learn More -
-
Ningetinib Tosylate
Catalog No. A17039 VEGF and PDGF inhibitorNingetinib Tosylate,also known as CT-053Tosylate and DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration. CAS: 1394820-69-9 (free base) 1394820-77-9 (tosylate) Learn More -
BFH772
Catalog No. A16342 VEGFR2 inhibitorBFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. Learn More -
EG00229
Catalog No. A16237 neuropilin-1/VEGF-A inhibitorEG00229 is the first small molecule inhibitors of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM(125I-VEGF binding to PAE/NRP1 cells). Learn More -
Nintedanib esylate
Catalog No. A16197 RTK inhibitorNintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Learn More -
NVP-BAW2881
Catalog No. A12693 VEGFR inhibitorNVP-BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. Learn More -
NVP-ACC789
Catalog No. A13240 -
Altiratinib (DCC2701)
Catalog No. A14387 c-Met/VEGFR inhibitorAltiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Learn More -
BMS-817378
Catalog No. A15792 MET/VEGFR-2 inhibitorBMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833. Learn More -
Vandetanib trifluoroacetate
Catalog No. A15272 VEGFR/EGFR inhibitorVandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM. Learn More -
Toceranib phosphate
Catalog No. A15263 Toceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. Learn More -
Regorafenib monohydrate
Catalog No. A15218 Tyrosine kinase inhibitorRegorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. Learn More -
TAK-593
Catalog No. A13555 VEGFR/PDGFR inhibitorTAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. Learn More -
ODM-203
Catalog No. A19098 FGFR/VEGFR inhibitorODM-203 is a potent FGFR and VEGFR families inhibitor with IC50s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. Learn More -
ZM 323881 hydrochloride
Catalog No. A11954 VEGFR InhibitorZM 323881 is a potent and selective inhibitor of the kinase activity of the human vascular endothelial growth factor receptor 2 (VEGFR2/KDR). Learn More -
Buflomedil HCl
Catalog No. A11737 VEGFR AntagonistBuflomedil is a vasoactive agent used to treat peripheral vascular disease. Learn More -
Linifanib (ABT-869)
Catalog No. A10025 VEGFR/PDGFR inhibitorLinifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively. Learn More -
BMS-794833
Catalog No. A10154 c-Met inhibitorBMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol. Learn More
FILTER BY:
Shopping Options
- Actions
-
- Inhibitor (80)
- Antagonist (1)
- Target
Adooq Quality Guarantee
We promise all products perform as described.